aTyr Pharma Inc reports results for the quarter ended in March - Earnings Summary

aTyr Pharma

07/05/2024 13:00

* aTyr Pharma Inc  LIFE.OQ  reported a quarterly adjusted
loss
of 23 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -29 cents.  The mean expectation of five analysts for the
quarter was for a loss of 24 cents per share. Wall Street
expected results to range from -29 cents to -18 cents per share.
    * Revenue was $235.00 thousand​; analysts expected $20.00
thousand. 
    * aTyr Pharma Inc's reported EPS for the quarter was a loss
of 23
cents​.
    * The company reported a quarterly loss of $15.49 million.
    * aTyr Pharma Inc shares had fallen by 14.9% this
quarter and
gained 17.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 12.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for aTyr Pharma Inc
is $20.00 
This summary was machine generated from LSEG data May 7 at 12:00
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.24          -0.23          Beat
 Dec. 31 2023      -0.24          -0.25          Missed
 Sep. 30 2023      -0.23          -0.20          Beat
 Jun. 30 2023      -0.28          -0.22          Beat